

Attachment 1

Date of publication:

| | Full Name <i>(Art.1.01)</i> | HCPs:City of Principal Practice HCOs:city where registered <i>(Art. 3)</i> | Country of Principal Practice <i>(Schedule 1)</i> | Principal Practice Address <i>(Art. 3)</i> | Unique country identifier OPTIONAL <i>(Art. 3)</i> | Donations and Grants to HCOs <i>(Art. 3.01.1.a)</i> | Contribution to costs of Events <i>(Art. 3.01.1.b & 3.01.2.a)</i> | | | Fee for service and consultancy <i>(Art. 3.01.1.c & 3.01.2.c)</i> | | | TOTAL OPTIONAL | |
|--|---|--|--|---|---|---|---|-----|--|---|-----------|--|----------------|----------|
| | Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event | Registration Fees | Travel & Accommodation | Fees | Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract | | | | | | | | | |
| <i>INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</i> | | | | | | | | | | | | | | |
| HCPs | Johan C. Raeder | Oslo | Norway | Ullernchausseen 70 | | N/A | N/A | | | | NOK 8,370 | | NOK 8,370 | |
| | <i>OTHER, NOT INCLUDED ABOVE -where information cannot be disclosed on an individual basis for legal reasons</i> | | | | | | | | | | | | | |
| | Aggregate amount attributable to transfers of value to such Recipients - <i>Art. 3.02</i> | | | | | | N/A | N/A | | | | | | Optional |
| | Number of Recipients in aggregate disclosure - <i>Art. 3.02</i> | | | | | | N/A | N/A | | | | | | Optional |
| | % of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - <i>Art. 3.02</i> | | | | | | N/A | N/A | | | | | | N/A |
| <i>INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</i> | | | | | | | | | | | | | | |
| <i>OTHER, NOT INCLUDED ABOVE -where information cannot be disclosed on an individual basis for legal reasons</i> | | | | | | | | | | | | | | |
| HCOs | Aggregate amount attributable to transfers of value to such Recipients - <i>Art. 3.02</i> | | | | | | | | | | | | | Optional |
| | Number of Recipients in aggregate disclosure - <i>Art. 3.02</i> | | | | | | | | | | | | | Optional |
| | % of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - <i>Art. 3.02</i> | | | | | | | | | | | | | N/A |
| | AGGREGATE DISCLOSURE | | | | | | | | | | | | | |
| R&D | Transfers of Value Research & Development as defined - Article 3.04 and Schedule 1 | | | | | | | | | | | | | Optional |

Methodological Notes to be completed here....